Efficacy, safety, and treatment persistence of netakimab in patients with active psoriatic arthritis in real-world clinical practice: interim results of the post-marketing safety study BCD-085-NIS-03/SIRIUS
Journal: Modern Rheumatology Journal
Year: 2025

Objective : to evaluate the efficacy, safety, and treatment persistence of netakimab (NTK) in patients with active psoriatic arthritis (PsA) in realworld clinical practice at 52 weeks of follow-up. Material and methods . This observational prospective cohort study included 149 patients with active PsA receiving NTK treatment in accordance with clinical guidelines. As of the data cut-off (April 21, 2025), the median follow-up duration was 63 weeks (range: 22–117 weeks). The primary endpoint was t